[1]
|
Arbour, K.C. and Riely, G.J. (2019) Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review. JAMA—Journal of the American Medical Association, 322, 764-774.
https://doi.org/10.1001/jama.2019.11058
|
[2]
|
Bartholomew, C., Eastlake, L., Dunn, P., et al. (2017) EGFR Targeted Therapy in Lung Cancer: An Evolving Story. Respiratory Medicine Case Reports, 20, 137-140.
|
[3]
|
Maemondo, M. (2020) Potential of Combination Therapy in EGFR Mutated Lung Cancer. Annals of Translational Medicine, 8, 518. https://doi.org/10.21037/atm.2020.03.76
|
[4]
|
Ettinger, D.S., Wood, D.E., Aggarwal, C., et al. (2019) Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, 17, 1464-1472.
https://doi.org/10.6004/jnccn.2019.0059
|
[5]
|
Nemeth, T., Sperandio, M. and Mocsai, A. (2020) Neutrophils as Emerging Therapeutic Targets. Nature Reviews Drug Discovery, 19, 253-275. https://doi.org/10.1038/s41573-019-0054-z
|
[6]
|
Ren, W.H., Hou, J.F., Yang, C.G., et al. (2019) Extracellular Vesicles Secreted by Hypoxia Pre-Challenged Mesenchymal Stem Cells Promote Non-Small Cell Lung Cancer Cell Growth and Mobility as Well as Macrophage M2 Polarization via miR-21-5p Delivery. Journal of Experimental & Clinical Cancer Research, 38, 62.
|
[7]
|
Tanizaki, J., Haratani, K., Hayashi, H., et al. (2018) Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Journal of Thoracic Oncology, 13, 97-105.
https://doi.org/10.1016/j.jtho.2017.10.030
|
[8]
|
Sheng, L., Luo, M., Sun, X., et al. (2013) Serum Fibrinogen Is an Independent Prognostic Factor in Operable Nonsmall Cell Lung Cancer. International Journal of Cancer, 133, 2720-2725. https://doi.org/10.1002/ijc.28284
|
[9]
|
Wang, H., Zhao, J., Zhang, M., et al. (2018) The Combination of Plasma Fibrinogen and Neutrophil Lymphocyte Ratio (F-NLR) Is a Predictive Factor in Patients with Resectable Non Small Cell Lung Cancer. Journal of Cellular Physiology, 233, 4216-4224. https://doi.org/10.1002/jcp.26239
|
[10]
|
Wang, M., Zhang, G., Zhang, Y., et al. (2020) Fibrinogen Alpha Chain Knockout Promotes Tumor Growth and Metastasis through Integrin-AKT Signaling Pathway in Lung Cancer. Molecular Cancer Research, 18, 943-954.
|
[11]
|
Li, J., Wang, Y., Wu, Y., et al. (2021) Prognostic Value of Pretreatment Albumin to Globulin Ratio in Lung Cancer: A Meta-Analysis. Nutrition and Cancer, 73, 75-82. https://doi.org/10.1080/01635581.2020.1737155
|
[12]
|
Karageorgou, E. and Samanidou, V. (2014) Youden Test Application in Robustness Assays during Method Validation. Journal of Chromatography A, 1353, 131-139.
|
[13]
|
Schisterman, E.F., Perkins, N.J., Liu, A., et al. (2005) Optimal Cut-Point and Its Corresponding Youden Index to Discriminate Individuals Using Pooled Blood Samples. Epidemiology, 16, 73-81.
https://doi.org/10.1097/01.ede.0000147512.81966.ba
|
[14]
|
Chen, X., Zhang, L. and Liu, X. (2018) Association of Systemic Inflammation with Survival in EGFR Wild-Type Lung Cancer. Annals of Oncology, 29, IX155.
|
[15]
|
Serresi, M., Gargiulo, G., Proost, N., et al. (2016) Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer. Cancer Cell, 29, 17-31.
https://doi.org/10.1016/j.ccell.2015.12.006
|
[16]
|
Shiels, M.S., Pfeiffer, R.M., Hildesheim, A., et al. (2013) Circulating Inflammation Markers and Prospective Risk for Lung Cancer. Journal of the National Cancer Institute, 105, 1871-1880. https://doi.org/10.1093/jnci/djt309
|
[17]
|
Amaral, S.R., Casal Moura, M., Carvalho, J., et al. (2019) Prognostic Significance of Neutrophil-To-Lymphocyte Ratio (NLR) and Platelet-To-Lymphocyte Ratio (PLR) in Non-Small Cell Lung Cancer (NSCLC) Treated with Immune Checkpoint Inhibitors. Annals of Oncology, 30, I3.
|
[18]
|
Rapoport, B.L., Vorobiof, D.A., Langenhoven, L., et al. (2019) Prognostic Significance of Neutrophil/Lymphocyte ratio in Patients Undergoing Treatment with Nivolumab for Recurrent Non-Small Cell Lung Cancer. Annals of Oncology, 30, II61.
|
[19]
|
Xiao, Y., Cong, M., Li, J., et al. (2021) Cathepsin C Promotes Breast Cancer Lung Metastasis by Modulating Neutrophil Infiltration and Neutrophil Extracellular Trap Formation. Cancer Cell, 39, 423-437.
|
[20]
|
Choi, S.H., Kim, A.R., Nam, J.K., et al. (2018) Tumour-Vasculature Development via Endothelial-To-Mesenchymal Transition after Radiotherapy Controls CD44v6+ Cancer Cell and Macrophage Polarization. Nature Communications, 9, Article No. 5108. https://doi.org/10.1038/s41467-018-07470-w
|
[21]
|
Chen, Y.B., Song, Y.C., Du, W., et al. (2019) Tumor-Associated Macrophages: An Accomplice in Solid Tumor Progression. Journal of Biomedical Science, 26, 78.
|
[22]
|
Ruffell, B. and Coussens, L.M. (2015) Macrophages and Therapeutic Resistance in Cancer. Cancer Cell, 27, 462-472.
https://doi.org/10.1016/j.ccell.2015.02.015
|
[23]
|
Wang, J., Li, D., Cang, H., et al. (2019) Crosstalk between Cancer and Immune Cells: Role of Tumor-Associated Macrophages in the Tumor Microenvironment. Cancer Medicine, 8, 4709-4721. https://doi.org/10.1002/cam4.2327
|
[24]
|
Joshi, K., De Massy, M.R., Ismail, M., et al. (2019) Spatial Heterogeneity of the T Cell Receptor Repertoire Reflects the Mutational Landscape in Lung Cancer. Nature Medicine, 25, 1549-1559.
https://doi.org/10.1038/s41591-019-0592-2
|
[25]
|
Lu, Y., Xue, J., Deng, T., et al. (2020) Safety and Feasibility of CRISPR-Edited T Cells in Patients with Refractory Non-Small-Cell Lung Cancer. Nature Medicine, 26, 732-740. https://doi.org/10.1038/s41591-020-0840-5
|
[26]
|
Inomata, M., Kado, T., Okazawa, S., et al. (2019) Peripheral PD1-Positive CD4 T-Lymphocyte Count Can Predict Progression-Free Survival in Patients With Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor. Anticancer Research, 39, 6887-6893.
|